Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 15 1 2016 01 31 Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness? 82 86 EN Ragıp Ertaş Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Kemal Özyurt Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Sinem Yıldız Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Yılmaz Ulaş Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Abdullah Turasan Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Atıl Avcı Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey 2015 11 17 2015 11 18 Omalizumab is a recombinant humanized anti-Ig E monoclonal antibody used as the third line treatment of chronic spontaneous urticaria (CSU). We report four patients with severe antihistamine-resistant CSU, who developed angioedema, anaphylaxis and/or flare up of urticaria at different times following omalizumab therapy. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/691 https://ijaai.tums.ac.ir/index.php/ijaai/article/download/691/607